Intercept Pharmaceuticals Stock News

Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans) (Paris:ALIMP), a medical technology compan

The FDA decision has wiped out more than a third of Intercept’s market cap. Yet, the company remains the front runner in the NASH space. The current trading mul

Cantor Fitzgerald downgraded shares of Intercept Pharmaceuticals (NASDAQ:ICPT) from an overweight rating to a neutral rating in a research note published on Tuesday morning, BenzingaRatingsTable repor

Intercept Pharmaceuticals (NASDAQ:ICPT) had its price objective lowered by Stifel Nicolaus from $100.00 to $51.00 in a research report released on Monday, The Fly reports. Stifel Nicolaus currently ha

The New York court officers’ union has sued the state office that runs the court system, alleging it has failed to keep members safe from the coronavirus. Dennis Quirk, president of the New Y…

LOS ANGELES, CA / ACCESSWIRE / July 2, 2020 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intercept Pharmac

No pain, no gain goes the well-worn axiom. A stock market themed inverse can read: no gain, shareholder pain. You can currently apply the latter to Intercept Pharmaceuticals (ICPT). The small-cap biot

LOS ANGELES, CA / ACCESSWIRE / July 1, 2020 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intercept Pharmac

The biotech sector remains in focus with updates on coronavirus treatments and other pipeline developments.

Robert W. Baird cut shares of Intercept Pharmaceuticals (NASDAQ:ICPT) from an outperform rating to a neutral rating in a report issued on Tuesday morning, Benzinga reports. They currently have $52.00